Sage Therapeutics and the LIGHTWAVE Study Findings
Sage Therapeutics, Inc. (Nasdaq: SAGE) recently announced topline results from their critical Phase 2 LIGHTWAVE Study, focusing on dalzanemdor (SAGE-718) as a potential treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s Disease (AD). Conducted over a 12-week period, this randomized, double-blind, placebo-controlled study aimed to assess the efficacy of dalzanemdor in impacting cognitive function in affected participants.
Study Overview and Key Findings
The LIGHTWAVE Study encompassed 174 participants who underwent careful evaluation during the trial. The primary outcome measure utilized was the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score, assessed at Day 84. Unfortunately, the study did not reveal a statistically significant difference in the cognitive scores for those treated with dalzanemdor compared to the placebo group. This outcome has led Sage Therapeutics to reassess the future trajectory of dalzanemdor's development in Alzheimer's treatment.
Summary of LIGHTWAVE Study Results
The findings from the LIGHTWAVE Study are noteworthy:
- The intervention did not yield statistically significant improvements in the cognitive test scores.
- Dalzanemdor demonstrated a favorable safety profile, with most treatment-emergent adverse events classified as mild to moderate.
- Exploratory analyses also indicated no significant differences between the dalzanemdor treatment group and the placebo group on other cognitive assessments, such as RBANS total score or MoCA total score.
The Next Steps for Dalzanemdor
In light of these findings, Sage Therapeutics has decided not to pursue further clinical development of dalzanemdor for Alzheimer’s Disease. However, the company remains focused on its ongoing Phase 2 DIMENSION Study, evaluating dalzanemdor for cognitive impairment associated with Huntington's Disease. Results from this study are expected to provide further insights into the drug's potential applications.
Insights from Sage Therapeutics' CEO
Barry Greene, CEO of Sage Therapeutics, expressed gratitude towards participants and contributors to the LIGHTWAVE Study, emphasizing the complexities surrounding Alzheimer's Disease. He stated, "While we are disappointed by the results of the LIGHTWAVE Study, we recognize the critical need for more effective treatments for individuals suffering from mild cognitive impairment and mild dementia related to Alzheimer’s. Our commitment is to foster research that informs and guides future studies in this area."
About Dalzanemdor (SAGE-718)
Dalzanemdor is a unique investigational compound classified as an NMDA receptor positive allosteric modulator (PAM). Although its primary focus has been on Alzheimer's, Sage Therapeutics is also exploring its efficacy in other cognitive disorders, including Huntington’s Disease. The commitment to research and development remains a core aspect of Sage's operations as they strive to meet unaddressed needs in brain health.
About Sage Therapeutics
Founded in 2010 and based in Cambridge, Mass., Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company dedicated to advancing innovative treatments that can significantly improve brain health. Sage is recognized for developing two FDA-approved medications for postpartum depression and is actively expanding its pipeline to address unmet medical needs in the domain of mental health and cognitive function. You can learn more about their endeavors on their official website, social media platforms, and other engagement avenues.
Frequently Asked Questions
What is dalzanemdor (SAGE-718)?
Dalzanemdor is an investigational medication designed as an NMDA receptor positive allosteric modulator, primarily studied for cognitive impairment in Alzheimer’s Disease and Huntington’s Disease.
What were the results of the LIGHTWAVE Study?
The LIGHTWAVE Study did not show statistically significant improvements in cognitive test scores among participants treated with dalzanemdor compared to those receiving a placebo.
Is Sage Therapeutics continuing development of dalzanemdor?
Sage Therapeutics has decided not to pursue further clinical development of dalzanemdor for Alzheimer's Disease after the LIGHTWAVE Study results.
What future studies are planned for dalzanemdor?
Sage Therapeutics is focusing on the ongoing Phase 2 DIMENSION Study for cognitive impairment associated with Huntington’s Disease, with results expected later this year.
How is Sage Therapeutics related to Alzheimer's treatment?
Sage Therapeutics is involved in research and development of treatments for brain health, including promising studies aiming to address cognitive impairments related to Alzheimer’s Disease.
